The impact of vaccination on *Neisseria gonorrhoeae* antimicrobial resistance and prevalence in men who have sex with men: a mathematical modelling study

Janneke C.M. Heijne, Maria Xiridou, Katy M.E. Turner, Maartje Basten, Maartje Visser, Birgit van Benthem, Nicola Low.

Contents

| Supplement 1: Details of the model | p. 2 |
|---|-------|
| Supplement 2: Gonorrhoea positivity and behavioral parameters | p. 9 |
| Supplement 3: Fitting procedure | p. 10 |
| Supplement 4: Uncertainty analyses | p. 12 |
| Supplement 5: Extended reference list from main text | p. 16 |

Supplement 1: Details of the model

The model consists of 66 differential equations. Men can either be susceptible (S), infected and unvaccinated (\hat{I}) or infected and vaccinated (\hat{I}). In the notation below, the first subscript denotes the risk group k, where k={1,2,3}={low, medium, high}, the second subscript denotes whether the infection is symptomatic (0) or asymptomatic (1) and the third subscript denotes whether the infection is fully sensitive to antibiotics (0), has intermediate sensitivity MIC values (1), reduced sensitivity MIC values (2) or is resistant (3). Thus, $I_{k,10}$ indicates an unvaccinated man from risk class k who is asymptomatically infected with the fully sensitive strain and $\hat{I}_{k,03}$ a vaccinated man from risk class k who is symptomatically infected with the resistant strain. The superscript "k" refers to the state in which first line treatment was not effective and people are waiting for their results from gonorrhoea culture and susceptibility testing and effective treatment (present for the reduced sensitivity and resistant strain).

All parameters are described in Table S1.1, and a graphical depiction of the model can be found in Figure S1.1.

Unvaccinated:

Susceptible:

$$\begin{split} \frac{dS_k}{dt} &= \mu N_k + \left(\theta - cov_k - \lambda_{k,0} - \lambda_{k,1} - \lambda_{k,2} - \lambda_{k,3} - \mu\right) S_k + \alpha_0 (1 - \tau_\alpha) I_{k,00} + \alpha_0 (1 - \tau_\alpha) I_{k,01} \\ &\quad + \alpha_0 (1 - \delta_2) (1 - \tau_\alpha) I_{k,02} + \alpha_{02}^w I_{k,02}^w + \alpha_0 (1 - \delta_3) I_{k,03} + \alpha_{03}^w I_{k,03}^w \\ &\quad + \alpha_{k,1} (1 - \tau_\alpha) I_{k,10} + \alpha_{k,1} (1 - \tau_\alpha) I_{k,11} + \alpha_{k,1} (1 - \delta_2) (1 - \tau_\alpha) I_{k,12} \\ &\quad + \alpha_{k,1} (1 - \delta_3) I_{k,13} - \kappa S_k + \kappa N_k \sum_{j=1}^3 S_j \\ &\quad + \gamma \left(I_{k,00} + I_{k,01} + I_{k,02} + I_{k,02}^w + I_{k,03} + I_{k,03}^w + I_{k,10} + I_{k,11} + I_{k,12} + I_{k,13} \right) \end{split}$$

Symptomatically infected:

$$\frac{dI_{k,00}}{dt} = \zeta \lambda_{k,0} S_k - (\gamma + \mu) I_{k,00} + \theta \hat{I}_{k,00} - (\alpha_0 + \tau) I_{k,00} - \kappa I_{k,00} + \kappa N_k \sum_{i=1}^{3} I_{j,00}$$

$$\frac{dI_{k,01}}{dt} = \zeta \lambda_{k,1} S_k - (\gamma + \mu) I_{k,01} + \theta \hat{I}_{k,01} - (\alpha_0 + \tau) I_{k,01} + (\alpha_0 \tau_\alpha + \tau) I_{k,00} - \kappa I_{k,01} + \kappa N_k \sum_{i=1}^{3} I_{j,01}$$

$$\frac{dI_{k,02}}{dt} = \zeta \lambda_{k,2} S_k - (\gamma + \mu) I_{k,02} + \theta \hat{I}_{k,02} - (\alpha_0 + \tau) I_{k,02} + (\alpha_0 \tau_\alpha + \tau) I_{k,01} - \kappa I_{k,02} + \kappa N_k \sum_{j=1}^{3} I_{j,02}$$

$$\frac{dI_{k,02}^{w}}{dt} = \alpha_0 \delta_2 (1 - \tau_\alpha) I_{k,02} - (\gamma + \mu) I_{k,02}^{w} + \theta \hat{I}_{k,02}^{w} - \alpha_{02}^{w} I_{k,02}^{w} - \kappa I_{k,02}^{w} + \kappa N_k \sum_{i=1}^{3} I_{j,02}^{w}$$

$$\frac{dI_{k,03}}{dt} = \zeta \lambda_{k,3} S_k - (\gamma + \mu) I_{k,03} + \theta \hat{I}_{k,03} - \alpha_0 I_{k,03} + \tau I_{k,02} - \kappa I_{k,03} + \kappa N_k \sum_{j=1}^{3} I_{j,03}$$

$$\frac{dI_{k,03}^{w}}{dt} = \alpha_0 \delta_3 I_{k,03}^{w} + \alpha_0 \tau_{\alpha} I_{k,02} - (\gamma + \mu) I_{k,03}^{w} + \theta \hat{I}_{k,03}^{w} - \alpha_{03}^{w} I_{k,03}^{w} - \kappa I_{k,03}^{w} + \kappa N_k \sum_{j=1}^{3} I_{j,03}^{w}$$

Asymptomatically infected:

$$\frac{dI_{k,10}}{dt} = (1 - \zeta)\lambda_{k,0}S_k - (\gamma + \mu)I_{k,10} + \theta\hat{I}_{k,10} - (\alpha_{k,1} + \tau)I_{k,10} - \kappa I_{k,10} + \kappa N_k \sum_{i=1}^{3} I_{j,10}$$

$$\begin{split} \frac{dI_{k,11}}{dt} &= (1-\zeta)\lambda_{k,1}S_k - (\gamma+\mu)I_{k,11} + \theta\hat{I}_{k,11} - (\alpha_{k,1}+\tau)I_{k,11} + (\alpha_{k,1}\tau_\alpha + \tau)I_{k,10} - \kappa I_{k,11} \\ &+ \kappa N_k \sum_{i=1}^3 I_{j,11} \end{split}$$

$$\begin{split} \frac{dI_{k,12}}{dt} &= (1-\zeta)\lambda_{k,2}S_k - (\gamma+\mu)I_{k,12} + \theta\hat{I}_{k,12} - \left(\alpha_{k,1}(1-\delta_2) + \tau\right)I_{k,12} + \left(\alpha_{k,1}\tau_\alpha + \tau\right)I_{k,11} - \kappa I_{k,12} \\ &+ \kappa N_k \sum_{j=1}^3 I_{j12} \end{split}$$

$$\begin{split} \frac{dI_{k,13}}{dt} &= (1-\zeta)\lambda_{k,3}S_k - (\gamma+\mu)I_{k,13} + \theta\hat{I}_{k,13} - \alpha_{k,1}(1-\delta_3)I_{k,13} + \left(\alpha_{k,1}(1-\delta_2)\tau_\alpha + \tau\right)I_{k,12} \\ &- \kappa I_{k,13} + \kappa N_k \sum_{j=1}^3 I_{j,13} \end{split}$$

Vaccinated:

Susceptible:

$$\begin{split} \frac{d\hat{S}_k}{dt} &= \left(cov_k - \theta - \hat{\lambda}_{k,0} - \hat{\lambda}_{k,1} - \hat{\lambda}_{k,2} - \hat{\lambda}_{k,3} - \mu\right) \hat{S}_k + \alpha_0 (1 - \tau_\alpha) \hat{I}_{k,00} + \alpha_0 (1 - \tau_\alpha) \hat{I}_{k,01} \\ &+ \alpha_0 (1 - \delta_2) (1 - \tau_\alpha) \hat{I}_{k,02} + \alpha_{02}^w \hat{I}_{k,02}^w + \alpha_0 (1 - \delta_3) \hat{I}_{k,03} + \alpha_{03}^w \hat{I}_{k,03}^w \\ &+ \alpha_{k,1} (1 - \tau_\alpha) \hat{I}_{k,10} + \alpha_{k,1} (1 - \tau_\alpha) \hat{I}_{k,11} + \alpha_{k,1} (1 - \delta_2) (1 - \tau_\alpha) \hat{I}_{k,12} \\ &+ \alpha_{k,1} (1 - \delta_3) \hat{I}_{k,13} - \kappa \hat{S}_k + \kappa N_k \sum_{j=1}^3 \hat{S}_j \\ &+ \gamma f_d \left(\hat{I}_{k,00} + \hat{I}_{k,01} + \hat{I}_{k,02} + \hat{I}_{k,02}^w + \hat{I}_{k,03} + \hat{I}_{k,03}^w + \hat{I}_{k,10} + \hat{I}_{k,11} + \hat{I}_{k,12} + \hat{I}_{k,13}\right) \end{split}$$

Symptomatically infected:

$$\begin{split} \frac{d\hat{l}_{k,00}}{dt} &= \zeta \hat{\lambda}_{k,0} \hat{S}_k - (\gamma f_d + \mu + \theta) \hat{l}_{k,00} - (\alpha_0 + \tau) \hat{l}_{k,00} - \kappa \hat{l}_{k,00} + \kappa N_k \sum_{j=1}^3 \hat{l}_{j,00} \\ \frac{d\hat{l}_{k,01}}{dt} &= \zeta \hat{\lambda}_{k,1} \hat{S}_k - (\gamma f_d + \mu + \theta) \hat{l}_{k,01} - (\alpha_0 + \tau) \hat{l}_{k,01} + (\alpha_0 \tau_\alpha + \tau) \hat{l}_{k,00} - \kappa \hat{l}_{k,01} + \kappa N_k \sum_{j=1}^3 \hat{l}_{j,01} \\ \frac{d\hat{l}_{k,02}}{dt} &= \zeta \hat{\lambda}_{k,2} \hat{S}_k - (\gamma f_d + \mu + \theta) \hat{l}_{k,02} - (\alpha_0 + \tau) \hat{l}_{k,02} + (\alpha_0 \tau_\alpha + \tau) \hat{l}_{k,01} - \kappa \hat{l}_{k,02} + \kappa N_k \sum_{j=1}^3 \hat{l}_{j,02} \\ \frac{d\hat{l}_{k,02}^w}{dt} &= \alpha_0 \delta_2 (1 - \tau_\alpha) \hat{l}_{k,02} - (\gamma f_d + \mu + \theta) \hat{l}_{k,02}^w - \alpha_{02}^w \hat{l}_{k,02}^w - \kappa \hat{l}_{k,02}^w + \kappa N_k \sum_{j=1}^3 \hat{l}_{j,02}^w \\ \frac{d\hat{l}_{k,03}}{dt} &= \zeta \hat{\lambda}_{k,3} \hat{S}_k - (\gamma f_d + \mu + \theta) \hat{l}_{k,03} - \alpha_0 \hat{l}_{k,03} + \tau \hat{l}_{k,02} - \kappa \hat{l}_{k,03} + \kappa N_k \sum_{j=1}^3 \hat{l}_{j,03} \\ \frac{d\hat{l}_{k,03}^w}{dt} &= \alpha_0 \delta_3 \hat{l}_{k,03} + \alpha_0 \tau_\alpha \hat{l}_{k,02} - (\gamma f_d + \mu + \theta) \hat{l}_{k,03}^w - \alpha_{03}^w \hat{l}_{k,03}^w - \kappa \hat{l}_{k,03}^w + \kappa N_k \sum_{j=1}^3 \hat{l}_{j,03}^w \\ \frac{d\hat{l}_{k,03}^w}{dt} &= \alpha_0 \delta_3 \hat{l}_{k,03} + \alpha_0 \tau_\alpha \hat{l}_{k,02} - (\gamma f_d + \mu + \theta) \hat{l}_{k,03}^w - \alpha_{03}^w \hat{l}_{k,03}^w - \kappa \hat{l}_{k,03}^w + \kappa N_k \sum_{j=1}^3 \hat{l}_{j,03}^w \\ \end{pmatrix}$$

Asymptomatically infected:

$$\begin{split} \frac{d\hat{I}_{k,10}}{dt} &= (1-\zeta)\hat{\lambda}_{k,0}\hat{S}_k - (\gamma f_d + \mu + \theta)\hat{I}_{k,10} - (\alpha_{k,1} + \tau)\hat{I}_{k,10} - \kappa\hat{I}_{k,10} + \kappa N_k \sum_{j=1}^3 \hat{I}_{j,10} \\ \frac{d\hat{I}_{k,11}}{dt} &= (1-\zeta)\hat{\lambda}_{k,1}\hat{S}_k - (\gamma f_d + \mu + \theta)\hat{I}_{k,11} - (\alpha_{k,1} + \tau)\hat{I}_{k,11} + (\alpha_0\tau_\alpha + \tau)\hat{I}_{k,10} - \kappa\hat{I}_{k,11} \\ &+ \kappa N_k \sum_{j=1}^3 \hat{I}_{j,11} \\ \frac{d\hat{I}_{k,12}}{dt} &= (1-\zeta)\hat{\lambda}_{k,2}\hat{S}_k - (\gamma f_d + \mu + \theta)\hat{I}_{k,12} - (\alpha_{k,1}(1-\delta_2) + \tau)\hat{I}_{k,12} + (\alpha_0\tau_\alpha + \tau)\hat{I}_{k,11} - \kappa\hat{I}_{k,12}d \\ &+ \kappa N_k \sum_{j=1}^3 \hat{I}_{j,12} \end{split}$$

$$\frac{d\hat{I}_{k,13}}{dt} = (1 - \zeta)\hat{\lambda}_{k,3}\hat{S}_k - (\gamma f_d + \mu + \theta)\hat{I}_{k,13} - \alpha_{k,1}(1 - \delta_3)\hat{I}_{k,13} + \tau\hat{I}_{k,12} - \kappa\hat{I}_{k,13} + \kappa N_k \sum_{i=1}^{3} \hat{I}_{j,13}$$

The force of infection (per year) λ_{ki} for unvaccinated and $\hat{\lambda}_{ki}$ for vaccinated per risk class k=1,2,3, and infection strain i=0,1,2,3 (0=fully sensitive strain, 1= intermediate sensitivity, 2=reduced sensitivity, 3=resistant) is given by:

$$\begin{split} \lambda_{k,0} &= c_k \sum_{j=1}^3 m_{kj} \left(\beta \frac{I_{j,00} + I_{j,10}}{N_j} + \beta f_t \frac{\hat{I}_{j,00} + \hat{I}_{j,10}}{N_j} \right) \\ \lambda_{k,1} &= c_k \sum_{j=1}^3 m_{kj} \left(\beta \psi \frac{I_{j,01} + I_{j,11}}{N_j} + \beta \psi f_t \frac{\hat{I}_{j,01} + \hat{I}_{j,11}}{N_j} \right) \\ \lambda_{k,i} &= c_k \sum_{j=1}^3 m_{kj} \left(\beta \psi \frac{I_{j,0i} + I_{j,1i}^w + I_{j,1i}}{N_j} + \beta \psi f_t \frac{\hat{I}_{j,0i} + \hat{I}_{j,1i}^w + \hat{I}_{j,1i}}{N_j} \right), i = 2,3 \\ \hat{\lambda}_{k,0} &= c_k \sum_{j=1}^3 m_{kj} \left(\beta f_s \frac{I_{j,00} + I_{j,10}}{N_j} + \beta f_t f_s \frac{\hat{I}_{j,00} + \hat{I}_{j,10}}{N_j} \right) \\ \hat{\lambda}_{k,1} &= c_k \sum_{j=1}^3 m_{kj} \left(\beta \psi f_s \frac{I_{j,01} + I_{j,11}}{N_j} + \beta \psi f_t f_s \frac{\hat{I}_{j,01} + \hat{I}_{j,11}}{N_j} \right) \\ \hat{\lambda}_{k,i} &= c_k \sum_{j=1}^3 m_{kj} \left(\beta \psi f_s \frac{I_{j,01} + I_{j,11}}{N_j} + \beta \psi f_t f_s \frac{\hat{I}_{j,01} + \hat{I}_{j,1i}}{N_j} \right), i = 2,3 \end{split}$$

The force of infection takes into account the fitness costs of the resistant strain, and the reductions in transmissibility or susceptibility when vaccinated. The force of infection depends on the partner change rates and mixing between MSM. Mixing is described by a matrix with the elements m_{ij}

$$m_{ij} = \omega \frac{c_j N_j}{\sum_{p=1}^3 c_p N_p} + (1 - \omega) \kappa_{ij}$$

Where $\kappa_{ij}=1$ if i=j and $\kappa_{ij}=0$ otherwise.

The model is programmed in Wolfram Mathematica 11. The code is available upon request.




Figure S1.1. Schematic overview of the model in asymptomatically (top) and symptomatically (bottom) infected MSM who are unvaccinated (left) or vaccinated (right) and in risk class *k*.

 Table S1.1. Overview of all parameters.

| Symbol | Explanation | Baseline value [Min-Max range]* |
|----------------------|---|---|
| Population | on | |
| $1/\mu$ | Duration of sexual active life (years) | 45 |
| N_{k} | Proportion (%) sexual activity class k (low, medium, high) | (0.715, 0.261, 0.024) |
| Infection | | |
| $1/\gamma$ | Duration of infection (months) | 4.5 |
| ζ | Proportion of infections being symptomatic | 0.3 |
| β | Transmission probability per sex act | 0.37 [0.36 – 0.40] |
| 1-ψ | Fitness cost (%) | 0 |
| au | Rate of mutant strain selection during the infectious period resulting in strain with higher MIC values | 0.00413 [0.0038 - 0.0053]** |
| $	au_lpha$ | Rate of mutant strain selection upon ceftriaxone treatment resulting in strain with higher MIC values | 0.00318 [0.0026 - 0.0032]** |
| Sexual b | ehaviour | |
| ω | Mixing (0: assortative 1: proportionate) | 0.79 [0.74 – 1.00] |
| K | Redistribution rate to same or other activity class (per year) | 0.2 |
| C_k | Contact rate (number of partners or CAI acts per year) for sexual activity class k (low, medium, high) | (6.56, 12.77, 36.12) |
| Testing o | and treatment | |
| $1/\alpha_0$ | Average time from infection to treatment symptomatics (days) | 14 |
| δ_2 | Treatment failure among people infected with reduced sensitivity MIC levels strain (%) | 0.5 |
| δ_3 | Treatment failure among people infected with resistant MIC levels strain (%) | 20 |
| $1/\alpha_{0,2}^{w}$ | Average time between treatment failure and successful treatment among symptomatic infected men with the reduced sensitivity strain (days) | 21 |
| $1/\alpha_{0,3}^{w}$ | Average time between treatment failure and successful treatment among symptomatic infected men with resistant strain (days) | 31 |
| Ok,1 | Testing rate (per year) asymptomatic infected individuals in activity class k (low, medium, high) | (0.18 [0.05 - 0.20], 0.25 [0.20 - 0.50], |

| | | 1.48 [0.50 – 1.49]) |
|----------------|---|---------------------|
| Vaccinat | tion | |
| $1/\theta$ | Duration of vaccine protection (years) | 2 |
| $1/f_d$ | Factor influencing duration of infection when vaccinated | NA |
| $1-f_t$ | Factor determining the reduction in transmission when infected and vaccinated | NA |
| 1- f s | Factor determining the reduction in susceptibility when vaccinated | 0.3 |
| cov_k | Vaccination uptake sexual activity class k (low, medium, high) | (0, 0, 0.4) |

NA: not applicable in baseline analyses. These are used in the uncertainty analyses.

^{*} The minimum and maximum values of the used 343 parameter sets (see supplement 3).

^{**} In the uncertainty analyses, one rate of developing a mutation resulting in strain with higher MIC values was set to zero, and the other one was fitted to the MIC curve and vice versa.

Supplement 2: Gonorrhoea positivity and behavioral parameters

The partner change rates and percentages of people in each of the activity classes are informed by the Amsterdam Cohort Studies on HIV and AIDS (ACS) and are based on [1]. In short, the ACS is a population based open cohort study on the epidemiology, psychosocial determinants, course of infection and pathogenesis of HIV. It is an open cohort, and once enrolled, MSM receive bi-annual STI and HIV testing and fill out a questionnaire [2]. To define the sexual activity classes in [1], data was used from 803 HIV-negative MSM who participated in the ACS between May 2007 and January 2017, which resulted in a total of 8,198 visits. A risk score was developed incorporating behavioral factors predictive of HIV seroconversion (including number of anal intercourse partners, condom use and group sex). These factors are also well known factors of acquiring a gonorrhoea infection. Based on this risk score, we defined three levels of sexual activity (low, medium and high), which determined the group size of each class [1]. The partner change rates for each sexual activity class was based on the average number of casual partners with whom men reported having condomless anal intercourse or oral intercourse in the last half year. This was multiplied by 1.5 [1] to obtain number of partners in the last year per risk group.

We also used the average percentage of people with a gonorrhea diagnosis (at any anatomical location, including pharyngeal, urogenital and anorectal location) in the past six months in each sexual activity class (Table S3.2). Between October 2008 and January 2017, gonorrhea was tested in the ACS at 6,963 visits. Self-collected anal swab and urine sample were tested using nucleic acid amplification tests (NAATs; Aptima combo 2, Hologic, Marlborough, MA, USA). This is used as prevalence to fit the unknown parameters of the model to (see Supplement 3).

Supplement 3: Fitting procedure

Gonorrhoea prevalence

We fitted the unknown parameters to the risk-group specific prevalence as reported in the ACS. We defined uniform probability distributions for all unknown parameters (Table S3.1)

Table S3.1. The distributions for each parameter used in the fitting.

| Parame | eter | Distribution |
|--------------|--|--------------|
| ω | Mixing | U[0,1] |
| $lpha_{L,1}$ | Testing rate asymptomatic infected individuals low risk | U[0·05, 0·2] |
| $lpha_{M,1}$ | Testing rate asymptomatic infected individuals medium risk | U[0·2, 0·5] |
| $lpha_{H,1}$ | Testing rate asymptomatic infected individuals high risk | U[0·5,1·5] |

The distributions were then sampled 4900 times using Latin hypercube sampling. For each parameter set, the transmission probability (β) was fitted to the risk group specific steady state prevalence by minimizing the sum of the squared residuals. Of the 4900 parameter sets, 3863 (79%) resulted in a beta that was between 0 and 1. Of those, we selected the first 500 parameter set that resulted in the lowest sum of the squared residuals. These 500 parameters were then used to fit the rate of developing a mutation resulting in strain with higher MIC values.

AMR – baseline analyses

To determine the two rates of developing a mutation resulting in strain with higher MIC values (i.e. during the infectious period and upon treatment), the model was than run into steady state with the fully sensitive strain only after which treatment with ceftriaxone was introduced in 2006 [3]. The mutation probabilities were fitted to the MIC curves for ceftriaxone from the Dutch GRAS surveillance for the years 2015 – 2019 [4]. This was also done by minimizing the sum of the squared residuals. Of the 500 parameter sets, 343 (68.6%) resulted in a good fit and could be used.

The parameter set that provided the best fit (lowest sum of squared residuals) was used as baseline values and the 343 parameter sets provide the input for the 95% credible intervals in all analyses.

Table S3.2. Prevalence from the data and the model.

| Activity class | Data | Model | |
|----------------|-----------------------------|----------------------------------|--|
| | % (95% confidence interval) | Baseline (95% credible interval) | |
| Overall | 3.0% (2.6% – 3.5%) | 3·4% (3·2% – 3·8%) | |
| Low | 1.7% (1.4% – 2.1%) | 2.5% (2.4% – 3.0%) | |
| Medium | 5.5% (4.5% – 6.6%) | 5.0% (4.5% – 5.4%) | |
| High | 12.4% (8.0% – 18.2%) | 12.5% (12.1% – 12.7%) | |

AMR – uncertainty analyses

We performed an uncertainty analyses by fitting the model to the MIC curve by assuming that new strain development could only happen upon treatment. This was also done by minimizing the sum of the squared residuals. Of the 500 parameter sets, 190 (38%) resulted in a good fit and could be used. The median resulting rate of developing a mutation resulting in strain with higher MIC values upon treatment was 0.012 (min: 0.011, max: 0.023).

For the uncertainty analyses assuming that new strain development could only happen upon treatment, all 500 parameter sets could be used. The median resulting rate of developing a mutation resulting in strain with higher MIC values during infectious period was 0.0063 (min: 0.0063, max: 0.0063).

The uncertainty analyses assuming that the new strains were less fit (i.e. 5% lower transmission probability) and both forms of new strain development (upon treatment and during infectious period) were more difficult to fit: only 4 of 500 parameter sets could be used (all others resulted in a negative rate). The median rate of developing a mutation resulting in strain with higher MIC values upon treatment was 0.0065 (min: 0.0060, max: 0.0066) and rate of developing a mutation resulting in strain with higher MIC values during infectious period was 0.0099 (min: 0.0098, max: 0.0104).

Supplement 4: Uncertainty analyses

Table S4.1 Effect on prevalence and relative reduction of prevalence (in 2050) of a partially protective vaccine that reduces **transmissibility** of *N*. *gonorrhoeae* for a vaccine with vaccine effectiveness(VE) of 30% and different vaccination uptake in high activity MSM or a vaccination uptake of 40% and different VE.

| | | Overall | | Non-resistant strains | | AMR | |
|-----------------|---------------|--------------------|-----------------------|-----------------------|-----------------------|-----------------|--|
| | | Prevalence | Relative reduction | Prevalence | Relative reduction | Prevalence | |
| | | % (95% CrI*) | % (95% CrI*) | % (95% CrI*) | % (95% CrI*) | % (95% CrI*) | |
| Baseline (fixed | VE of 30%) | | | | | | |
| Uptake | 0% | 4.0 (3.6 -5.0) | 10·1 (2·9 – 46·9) | 3.2 (1.7 – 3.6) | -11-4 (-48-53-8) | 0.8 (0.2 - 3.2) | |
| | 20% | 3.1 (2.7 – 4.0) | -15·2 (-20·3 – 13·1) | 2.5 (1.5 – 2.9) | -31·1 (-56·6 – -24·5) | 0.6 (0.2 - 2.3) | |
| | 40% | 2.5 (2.1 - 3.1) | -32·7 (-37·9 – -12·3) | 2.0 (1.2 - 2.3) | -45·6 (-64·3 – -38·5) | 0.4 (0.1 - 1.7) | |
| | 60% | 2.0 (1.7 – 2.5) | -45.0 (-50.4 – -29.0) | 1.6 (1.0 - 2.0) | -55·6 (-70·2 – -48·6) | 0.3 (0.1 - 1.3) | |
| | 80% | 1.7 (1.4 – 2.1) | -53·9 (-59·5 – -41·9) | 1.3 (0.8 – 1.7) | -62·9 (-74·8 – -55·9) | 0.3 (0.1 - 1.0) | |
| Baseline (fixed | uptake high ı | risk group of 40%) | | | | | |
| VE | 0% | 4.0 (3.6 – 5.0) | 10.1 (2.9 – 46.9) | 3.2 (1.7 – 3.6) | -11·4 (-48·5 – -3·8) | 0.8 (0.2 - 3.2) | |
| | 30% | 2.5 (2.1 - 3.1) | -32·7 (-37·9 – -12·3) | 2.0 (1.2 - 2.3) | -45·6 (-64·3 – -38·5) | 0.4 (0.1 - 1.7) | |
| | 50% | 1.4 (1.1 - 1.7) | -61·4 (-67·7 – -52·3) | 1.1 (0.6 - 1.5) | -68·8 (-79·7 – -61·9) | 0.2 (0.1 - 0.8) | |
| | 70% | 0.6 (0.3 -0.8) | -84.6 (-90.979.1) | 0.5 (0.2 - 0.7) | -87·2 (-94·1 – -81·1) | 0.1 (0.0 -0.2) | |
| | 90% | 0.2 (0.1 - 0.3) | -95·6 (-98·4 – -92·4) | 0.1 (0.0 - 0.3) | -96·2 (-98·9 – -92·9) | 0.0 (0.0 - 0.1) | |

Table S4.2 Effect on prevalence and relative reduction of prevalence (in 2050) of a partially protective vaccine that reduces the **duration of protection** of *N. gonorrhoeae* for a vaccine with vaccine effectiveness(VE) of 30% and different vaccination uptake in high activity MSM or a vaccination uptake of 40% and different VE.

| | | Overall | | Non-resistant strains | | AMR | |
|----------------|---------------|--------------------|----------------------------|-----------------------|-----------------------|-----------------|--|
| | | Prevalence | Relative reduction | Prevalence | Relative reduction | Prevalence | |
| | | % (95% Crl*) | % (95% CrI*) | % (95% CrI*) | % (95% Crl*) | % (95% CrI*) | |
| Baseline (fixe | d VE of 30%) | | | | | | |
| Uptake | 0% | 4.0 (3.6 -5.0) | 10·1 (2·9 – 46·9) | 3.2 (1.7 - 3.6) | -11·4 (-48·5 – -3·8) | 0.8 (0.2 - 3.2) | |
| | 20% | 3.4 (3.0 – 4.3) | -7·7 (-14·6 – 25·8) | 2.7 (1.6 - 3.1) | -25·2 (-53·0 – -19·3) | 0.6 (0.2 - 2.6) | |
| | 40% | 2.9 (2.5 – 3.8) | -20·1 (-27·6 – 9·3) | 2.3 (1.4 - 2.7) | -35·5 (-57·1 – -29·8) | 0.5 (0.2 - 2.2) | |
| | 60% | 2.6 (2.2 - 3.5) | -29.0 (-37.1 – -2.7) | 2.0 (1.3 - 2.4) | -43·2 (-60·4 – -37·1) | 0.5 (0.1 - 1.9) | |
| | 80% | 2.4 (1.9 – 3.1) | -35·7 (-44·4 – -12·2) | 1.8 (1.3 – 2.2) | -49.0 (-63.3 – -42.6) | 0.4 (0.1 - 1.7) | |
| Baseline (fixe | d uptake high | risk group of 40%) | | | | | |
| VE | 0% | 4.0 (3.6 – 5.0) | 10·1 (2·9 – 46·9) | 3.2 (1.7 - 3.6) | -11.4 (-48.5 – -3.8) | 0.8 (0.2 - 3.2) | |
| | 30% | 2.9 (2.5 - 3.8) | -20·1 (-27·6 – 9·3) | 2.3 (1.4 - 2.7) | -35·5 (-57·1 – -29·8) | 0.5 (0.2 - 2.2) | |
| | 50% | 1.9 (1.5 – 2.6) | -47·5 (-56·3 – -28·2) | 1.5 (1.0 - 1.9) | -58·2 (-68·9 – -51·7) | 0.3 (0.1 - 1.3) | |
| | 70% | 0.8 (0.5 - 1.1) | -78·7 (-85·4 – -70·3) | 0.6 (0.3 - 0.9) | -82·6 (-89·6 – -76·4) | 0.1 (0.0 - 0.4) | |
| | 90% | 0.1 (0.0 - 0.2) | -96·6 (-98·8 – -93·9) | 0.1 (0.0 - 0.2) | -97·2 (-99·1 – -94·4) | 0.0 (0.0 - 0.0) | |

Table S4.3 Effect on prevalence and relative reduction of prevalence (in 2050) of an **all-or-nothing vaccine** of *N. gonorrhoeae* for a vaccine with vaccine effectiveness(VE) of 30% and different vaccination uptake in high activity MSM or a vaccination uptake of 40% and different VE.

| | | Overall | | Non-resistant strains | | AMR | |
|-----------------|---------------|-------------------|------------------------------|-----------------------|-----------------------|-----------------|--|
| | | Prevalence | Relative reduction | Prevalence | Relative reduction | Prevalence | |
| | | % (95% CrI*) | % (95% CrI*) | % (95% CrI*) | % (95% CrI*) | % (95% CrI*) | |
| Baseline (fixed | VE of 30%) | | | | | | |
| Uptake | 0% | 4.0 (3.6 -5.0) | 10·1 (2·9 – 46·9) | 3.2 (1.7 - 3.6) | -11·4 (-48·5 – -3·8) | 0.8 (0.2 - 3.2) | |
| | 20% | 2.8 (2.4 – 3.6) | -23·8 (-29·0 – 1·5) | 2.2 (1.4 - 2.6) | -38·1 (-60·0 – -31·5) | 0.5 (0.2 - 2.0) | |
| | 40% | 1.7 (1.3 – 2.1) | -54·0 (-60·1 – -40·7) | 1.3 (0.8 – 1.7) | -63·0 (-74·5 – -56·2) | 0.3 (0.1 - 1.0) | |
| | 60% | 0.8 (0.5 - 1.1) | -77·6 (-84·4 <i></i> 71·7) | 0.6 (0.3 - 1.0) | -81·7 (-90·0 – -75·4) | 0.1 (0.0 - 0.4) | |
| | 80% | 0.3 (0.1 -0.5) | -91.0 (-95.5 – -86.2) | 0.3 (0.1 -0.5) | -92·4 (-96·9 – -87·6) | 0.0 (0.0 - 0.1) | |
| Baseline (fixed | uptake high r | isk group of 40%) | | | | | |
| VE | 0% | 4.0 (3.6 -5.0) | 10·1 (2·9 – 46·9) | 3.2 (1.7 - 3.6) | -11·4 (-48·5 – -3·8) | 0.8 (0.2 - 3.2) | |
| | 30% | 1.7 (1.3 – 2.1) | -54·0 (-60·1 – -40·7) | 1.3 (0.8 – 1.7) | -63·0 (-74·5 – -56·2) | 0.3 (0.1 - 1.0) | |
| | 50% | 0.6 (0.3 - 0.9) | -83·2 (-89·5 <i></i> 77·4) | 0.5 (0.2 - 0.8) | -86·2 (-93·1 – -80·2) | 0.1 (0.0 - 0.3) | |
| | 70% | 0.2 (0.1 - 0.3) | -95·2 (-98·1 – -91·6) | 0.1 (0.0 - 0.3) | -95·9 (-98·6 – -92·5) | 0.0 (0.0 - 0.1) | |
| | 90% | 0.0 (0.0 - 0.1) | -98·6 (-99·6 – -97·0) | 0.0 (0.0 - 0.1) | -98·8 (-99·7 – -97·3) | 0.0 (0.0 - 0.0) | |

References supplement

- 1. Rozhnova G, Heijne JCM, Basten M, den Daas C, Matser A, Kretzschmar M. Impact of sexual trajectories of men who have sex with men on the reduction in HIV transmission by preexposure prophylaxis. *Epidemics* 2019; **28**:100337.
- 2. van Bilsen WPH, Boyd A, van der Loeff MFS, et al. Diverging trends in incidence of HIV versus other sexually transmitted infections in HIV-negative men who have sex with men (MSM) in Amsterdam. *AIDS* 2020; **34**(2):301-309.
- Hofstraat SH, Gotz HM, van Dam AP, van der Sande MA, van Benthem BH. Trends and determinants of antimicrobial susceptibility of Neisseria gonorrhoeae in the Netherlands, 2007 to 2015. Euro Surveill 2018; 23(36):1700565
- 4. Staritsky LE, Van Aar F, Visser M, et al. Sexually transmitted infections, including HIV, in the Netherlands in 2018. Bilthoven: National Institute for Public Health and the Environment (RIVM), 2020.

Supplement 5: Extended reference list from main text

- s31. Basten M, Heijne JCM, Geskus R, Den Daas C, Kretzschmar M, Matser A. Sexual risk behaviour trajectories among MSM at risk for HIV in Amsterdam, the Netherlands. *AIDS* 2018; **32**(9): 1185-92.
- s32. Rozhnova G, Heijne JCM, Basten M, den Daas C, Matser A, Kretzschmar M. Impact of sexual trajectories of men who have sex with men on the reduction in HIV transmission by pre-exposure prophylaxis. *Epidemics* 2019; **28**: 100337.
- s33. Unemo M, Althaus CL. Fitness cost and benefit of antimicrobial resistance in Neisseria gonorrhoeae: Multidisciplinary approaches are needed. *PLoS Med* 2017; **14**(10): e1002423.
- s34. Taylor SN, Marrazzo J, Batteiger BE, et al. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. *N Engl J Med* 2018; **379**(19): 1835-45.
- s35. Fingerhuth SM, Low N, Bonhoeffer S, Althaus CL. Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study. *BMC Med* 2017; **15**(1): 142.
- s36. Dona V, Low N, Golparian D, Unemo M. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae. *Expert Rev Mol Diagn* 2017; **17**(9): 845-59.
- s37. Yaesoubi R, Cohen T, Hsu K, et al. Adaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States:

 A mathematical modeling study. *PLoS Med* 2020; **17**(4): e1003077.
- s38. Koplon S. NIH study to explore vaccine for gonorrhea prevention.

 https://www.uab.edu/news/health/item/10852-nih-study-to-explore-vaccine-for-gonorrhea-prevention [Accessed 10-09-2020].

- s39. Xiridou M, Lugner A, de Vries HJ, et al. Cost-Effectiveness of Dual Antimicrobial Therapy for Gonococcal Infections Among Men Who Have Sex With Men in the Netherlands. *Sex Transm Dis* 2016; **43**(9): 542-8.
- s40. Tuite AR, Gift TL, Chesson HW, Hsu K, Salomon JA, Grad YH. Impact of Rapid Susceptibility Testing and Antibiotic Selection Strategy on the Emergence and Spread of Antibiotic Resistance in Gonorrhea. *J Infect Dis* 2017; **216**(9): 1141-9.
- s41. Holmes KK, Sparling PF, Stamm WE, et al. Sexually Transmitted Diseases. Vol. 4th Edition. New York: McGraw-Hill; 2008.
- s42. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhea and Chlamydia using stochastic network simulations. *Am J Epidemiol* 1996; **144**(3): 306-17.
- s43. Barbee L, Soge O, Haglund M, et al. O02.4 Incidence and duration of pharyngeal and rectal gonorrhea and chlamydia among high-risk men who have sex with men (MSM). *Sex Transm Infect* 2019; **95**(Suppl 1): A40-A.
- s44. Spicknall IH, Mayer KH, Aral SO, Romero-Severson EO. Assessing uncertainty in an anatomical site-specific gonococcal infection transmission model of men who have sex with men. *Sex Transm Dis* 2019; **46**(5):321-328
- s45. Visser M, Heijne JC, Hogewoning AA, van Aar F. Frequency and determinants of consistent STI/HIV testing among men who have sex with men testing at STI outpatient clinics in the Netherlands: a longitudinal study. *Sex Transm Infect* 2017; **93**(6):396-403.